Research protocol guide for tissue repair peptides BPC-157, TB-500, and GHK-Cu. Preclinical dosage ranges, administration routes, cycling patterns, and stacking protocols with PubMed citations.
Last updated Jun 11, 2026·6 min read
Most protocol discussions start and end with a number — how many micrograms, how often, for how long. That number-chasing is exactly how protocol research gets misread, because the numbers are downstream of the pharmacology: every dose range, route, and cycle length in the published literature traces back to how each compound actually behaves in tissue.
**BPC-157 BPC-157 pentadecapeptide Gastrointestinal protection & systemic tissue repair , TB-500 TB-500 synthetic heptapeptide fragment (actin-binding domain of Thymosin Beta-4) Systemic tissue repair & angiogenesis , and GHK-Cu GHK-Cu copper-binding tripeptide Skin regeneration & collagen synthesis ** are three of the most studied tissue repair peptides in preclinical research, and their protocol profiles could hardly be more different — from BPC-157's unusual oral bioactivity to TB-500's systemic distribution to GHK-Cu's dual injectable and topical routes.
By the end of this guide, you will know why researchers dose these compounds the way they do: the dosage ranges reported in animal models, the administration routes explored, the cycling patterns used in longer studies, and the rationale behind multi-compound protocols. One transparency note up front rather than in a footer: everything here comes from published preclinical and early-phase research, none of it approved for therapeutic use in humans, and the purpose is educational — helping informed readers understand how these compounds are studied, not recommending any protocol for human application.
Start with the parameters themselves, because each one tells a story about the compound behind it.
I.Overview
Why are preclinical peptide protocols never round numbers? Because none of the parameters are arbitrary — dose, route, frequency, and duration each follow from the compound's pharmacokinetics, the target tissue, and the question the study is asking.
Dose selection typically starts from a compound's known bioavailability and scales by body weight. Rodent doses are then converted to human equivalents using the FDA's body surface area method, which divides the animal mg/kg dose by a species-specific factor — roughly 12.3 for rats and 6.2 for micePMID: 21030672 . For anyone reading a rodent study, that conversion is the bridge between what was published and what it might mean at human scale.
Route matters just as much, because route determines exposure. Subcutaneous injection gives sustained absorption through dermal vasculature; intramuscular offers faster systemic uptake. Oral delivery spares some compounds first-pass hepatic metabolism but exposes them to gastric degradation — which is precisely why BPC-157 BPC-157 pentadecapeptide Gastrointestinal protection & systemic tissue repair 's reported oral bioactivity stands out as pharmacologically noteworthy.
Cycle length follows the biology rather than convenience. Collagen remodeling, angiogenesis, and structural tissue reorganization are slow processes, so tissue repair research generally runs longer than acute-dose studies — weeks to months instead of days.
And stacking rests on complementarity: when two compounds reach the same biological outcome through different pathways, researchers theorize the combination may exceed the sum of its parts.
Each principle comes alive in the compound-specific protocols below — starting with the peptide found in stomach juice.
BPC-157 BPC-157 pentadecapeptide Gastrointestinal protection & systemic tissue repair 's protocol profile stands out for three reasons: multiple administration routes, an unusually wide dose range, and oral activity most peptides cannot match.
Subcutaneous injection is the most commonly studied route. Rodent studies typically use 2 to 10 µg/kg body weight once or twice daily PMID: 21030672 — which, after BSA normalization, corresponds to roughly 250 to 500 µg per day for a 70 kg adult. Intramuscular injection has been studied at similar ranges, with musculoskeletal research on tendons, ligaments, and muscle often injecting directly into or near the injury site itself.
Oral delivery is the plot twist. Multiple preclinical studies have demonstrated bioactivity through oral administration PMID: 21030672 , likely because the peptide derives from a protective protein in stomach mucosa — chemistry built by evolution to survive gastric conditions.
Intravenous administration has also entered the picture: a 2025 pilot safety study in healthy human volunteers found IV infusion of up to 20 mg well tolerated, with no adverse effects reported PMID: 40131143 .
Cycle durations track the injury model. Acute wound studies run 7 to 14 days; tendon and ligament repair models extend to 4 to 8 weeks; research on chronic conditions has used protocols lasting up to 12 weeks.
The pattern to notice: one compound, four routes, one consistent dose-response logic. How does that compare with a fragment that refuses to stay local?
TB-500 TB-500 synthetic heptapeptide fragment (actin-binding domain of Thymosin Beta-4) Systemic tissue repair & angiogenesis flips BPC-157 BPC-157 pentadecapeptide Gastrointestinal protection & systemic tissue repair 's protocol logic on its head: because actin regulation happens inside every cell, the compound distributes systemically — no site-specific injection required. Wherever the injury sits, the mechanism can reach it.
Rodent dosing typically runs 2 to 6 mg/kg body weight via subcutaneous or intraperitoneal injection PMID: 16099219 . The parent compound, Thymosin Beta-4 Thymosin Beta-4 naturally occurring 43-amino acid actin-sequestering peptide Actin-sequestering, tissue repair & angiogenesis , has been studied in human clinical trials at doses ranging from hundreds of micrograms to several milligrams.
A loading-and-maintenance structure dominates longer protocols: 2 to 4 weeks at higher doses to rapidly establish tissue concentrations, transitioning to lower maintenance doses for the remainder of the study.
Cycles run longer than BPC-157 BPC-157 pentadecapeptide Gastrointestinal protection & systemic tissue repair 's because the mechanism addresses later phases of the healing cascade — soft-tissue repair research commonly spans 4 to 12 weeks, and cardiac repair studies have extended to 16 weeks or beyond.
One more protocol enabler: the absence of significant off-target effects at effective doses PMID: 16099219 has allowed researchers to explore comparatively high dose ranges without confounding signals.
Systemic by design and slow-cycle by necessity, TB-500 TB-500 synthetic heptapeptide fragment (actin-binding domain of Thymosin Beta-4) Systemic tissue repair & angiogenesis sets up an interesting contrast with a compound that can simply be applied to skin.
GHK-Cu GHK-Cu copper-binding tripeptide Skin regeneration & collagen synthesis splits its protocol personality two ways: injectable and topical, with distinct parameters for each.
Subcutaneous research in rodent models typically uses 1 to 5 mg/kg body weightPMID: 26236730 ; exploratory human protocols have used 1 to 2 mg daily by subcutaneous injection.
Topical application is the clinically deeper route. Dermatological research has documented effects on skin aging markers, collagen density, and wound healing at concentrations of 0.5 to 2% in cream or serum formulationsPMID: 21030672 , with 8 to 12 weeks of daily application as the standard measurement window — long enough for collagen turnover to actually register in the data.
Protocol design also leans on the compound's endogenous baseline: plasma concentrations fall from approximately 200 ng/mL in young adults to less than 80 ng/mL by age 60 PMID: 26236730 .
Cycles often follow a stepped 30-day pattern — 15 days at a lower dose followed by 15 days higher — reflecting collagen synthesis's biological timeline of weeks rather than days.
Three compounds, three protocol philosophies. What happens when researchers line them up in the same study design?
skin-health wound-healing anti-aging
IV.How They Work Together
Why study all three at once? Because their protocol profiles slot into the same healing cascade without overlapping — and because practical compatibility matters as much as mechanism.
BPC-157 BPC-157 pentadecapeptide Gastrointestinal protection & systemic tissue repair typically anchors multi-peptide tissue repair protocols, combining broad mechanistic reach with site-specific injection capability PMID: 21030672 . TB-500 TB-500 synthetic heptapeptide fragment (actin-binding domain of Thymosin Beta-4) Systemic tissue repair & angiogenesis adds systemic coverage through an entirely different pathway — actin-mediated cell migration PMID: 16099219 — making the pair one of the most studied two-peptide protocols in the literature. GHK-Cu GHK-Cu copper-binding tripeptide Skin regeneration & collagen synthesis completes the sequence with copper-dependent collagen cross-linking and structural remodeling PMID: 26236730 .
Because the three operate through independent mechanisms with no known direct interactions, protocols can administer them simultaneously without pharmacological conflict.
The asterisk belongs in the same breath: mechanistic plausibility is not clinical evidence. No controlled human trial has ever studied the three-peptide combination — which makes understanding each compound individually the only honest foundation for evaluating any multi-compound design.
V.Frequently Asked Questions
Frequently Asked Questions
In rodent models, BPC-157 is typically studied at 2 to 10 µg/kg body weight via subcutaneous or intramuscular injection, once or twice daily [PMID: 21030672]. Using the FDA’s BSA normalization method [PMID: 25415472], this corresponds to approximately 250 to 500 µg per day for a 70 kg adult.
Most peptides are degraded by gastric acid and proteolytic enzymes. BPC-157 appears to be an exception — multiple preclinical studies have demonstrated bioactivity through oral administration [PMID: 21030672]. Its gastric origin may explain this resistance to GI degradation.
TB-500 and BPC-157 differ in route specificity, dose magnitude, and cycle duration. BPC-157 is often injected near the injury site; TB-500 at any convenient subcutaneous site because its mechanism is inherently systemic [PMID: 16099219]. TB-500 protocols also tend to run longer — 4 to 12 weeks.
The loading-maintenance pattern uses higher initial doses to rapidly establish tissue concentrations, followed by lower maintenance doses. Loading phases typically last 2 to 4 weeks at higher doses, transitioning to maintenance for the study’s duration.
Yes — topical application is GHK-Cu’s most clinically explored route. Dermatological studies have documented effects on skin aging markers, collagen density, and wound healing at concentrations of 0.5 to 2% [PMID: 25415472]. Clinical studies use 8 to 12 weeks of daily topical application.
GHK-Cu protocols often use a stepped approach — lower doses for the first 15 days, higher doses for the next 15 days — because collagen synthesis and cross-linking operate on a biological timeline of weeks, not days.
These three compounds operate through independent mechanisms with no known direct interactions [PMID: 21030672, PMID: 16099219, PMID: 26236730]. However, no controlled human trial has studied the three-peptide combination.
Duration depends on the target tissue. For acute soft tissue injuries, BPC-157 protocols span 1–3 weeks. For tendon and ligament repair, 4–8 weeks. TB-500 protocols commonly run 4–12 weeks. GHK-Cu dermatological studies standardize on 8–12 weeks.
The FDA’s body surface area normalization method converts animal doses to human equivalent doses [PMID: 23755725]. It divides the animal mg/kg dose by a species-specific factor — approximately 12.3 for rats and 6.2 for mice.
No. BPC-157, TB-500, and GHK-Cu are not approved by the FDA, EMA, or MHRA. The February 2026 FDA reclassification placed TB-500 as a 503A Category 2 bulk drug substance prohibited in compounding.
VI.Summary
The protocol records read like three biographies. BPC-157 BPC-157 pentadecapeptide Gastrointestinal protection & systemic tissue repair : versatile across subcutaneous, intramuscular, oral, and even intravenous routes. TB-500 TB-500 synthetic heptapeptide fragment (actin-binding domain of Thymosin Beta-4) Systemic tissue repair & angiogenesis : systemically distributed via subcutaneous injection, with longer cycle durations. GHK-Cu GHK-Cu copper-binding tripeptide Skin regeneration & collagen synthesis : bridging injectable and topical with copper-dependent mechanics.
What decades of preclinical investigation establish is that these are pharmacologically distinct tools with defined protocol profiles. What it does not establish is that any protocol produces safe and effective therapeutic outcomes in humans.
For the mechanistic basis, see the Healing Peptides Guide; for combination logic, the Healing Stack; and for the newest findings, current PubMed searches beat any static guide.
TB-500 
GHK-Cu 
BPC-157 pentadecapeptide Gastrointestinal protection & systemic tissue repair 's protocol profile stands out for three reasons: multiple administration routes, an unusually wide dose range, and oral activity most peptides cannot match.
Thymosin Beta-4